Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carboplatin
Drug ID BADD_D00364
Description Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. It is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
Marketing Status Prescription; Discontinued
ATC Code L01XA02
DrugBank ID DB00958
KEGG ID D01363
MeSH ID D016190
PubChem ID 426756
TTD Drug ID D0X7HM
NDC Product Code 0703-4239; 55150-335; 63592-0271; 68083-192; 49812-0010; 68554-0084; 53104-7570; 69448-005; 0703-4246; 54875-0002; 55150-386; 55150-334; 0703-4248; 55150-333; 63323-172; 72659-863; 68083-191; 71288-100; 16729-295; 0703-4244; 68083-193; 68083-190; 61703-339
Synonyms Carboplatin | cis-Diammine(cyclobutanedicarboxylato)platinum II | CBDCA | Paraplatin | Paraplatine | Platinwas | Ribocarbo | Carboplat | Neocarbo | Carbosin | Carbotec | Ercar | JM-8 | JM 8 | JM8 | Nealorin | NSC-241240 | NSC 241240 | NSC241240 | Blastocarb
Chemical Information
Molecular Formula C6H12N2O4Pt
CAS Registry Number 41575-94-4
SMILES C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.029039%
Abdominal pain lower07.01.05.0100.001865%Not Available
Abdominal pain upper07.01.05.0030.011988%
Acidosis14.01.03.0020.000533%
Actinic keratosis23.01.06.0010.001598%Not Available
Activated partial thromboplastin time prolonged13.01.02.0010.000533%
Acute hepatic failure09.01.03.0010.000347%Not Available
Acute lymphocytic leukaemia16.01.01.001; 01.10.01.0010.000278%Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.000973%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.002398%Not Available
Acute promyelocytic leukaemia16.01.05.003; 01.10.05.0030.000533%Not Available
Acute respiratory distress syndrome22.01.03.0010.000695%
Acute respiratory failure22.02.06.001; 14.01.04.0040.001181%Not Available
Adenocarcinoma16.16.01.0040.000208%Not Available
Aggression19.05.01.001--Not Available
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.0010.001865%Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.001598%Not Available
Anaemia01.03.02.0010.031170%
Anaphylactic reaction24.06.03.006; 10.01.07.0010.018382%
Anaphylactic shock24.06.02.004; 10.01.07.0020.015185%Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.0070.000799%Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.001332%
Angioedema10.01.05.009; 23.04.01.0010.005062%Not Available
Anuria20.01.03.0020.001066%Not Available
Anxiety19.06.02.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 25 Pages